Enjoy 20% off your first order · use code Free shipping on orders $100+ · free 2-Day $175+Ships today when you order before 3 PM ET

Compound ProfilesNovember 10, 202612 min readCodex Research Team

What Is BPC-157? Structure, Research and Testing

Explore products
CR
Codex Research TeamPublished November 10, 2026

12 min read18 cited sources15 FAQs

Chain of fifteen linked green glass spheres representing the amino-acid sequence of BPC-157, over a branching network of light
BPC-157 is a chain of fifteen amino acids. The sequence, not the name on the label, is what a certificate of analysis has to confirm.

BPC-157 is one of the most searched research peptides in the United States and one of the least understood. This profile covers what the molecule is, where its name comes from, which signalling pathways it is studied in, how much of the evidence holds up, and how to read the certificate for a specific lot.

Key takeaways

  • BPC-157 is a synthetic 15-amino-acid peptide, GEPPPGKPADDAGLV, with a molecular weight of about 1,419.5 Da. Its sequence was described in 1993 as a fragment of a larger protein found in gastric juice.
  • No single receptor has been confirmed. In cell models BPC-157 is linked to several signalling routes, including VEGFR2-Akt-eNOS, ERK1/2, Src-caveolin-1-eNOS and FAK-paxillin.
  • A 2025 systematic review found 36 eligible studies published between 1993 and 2024. Thirty-five were preclinical and one was clinical.
  • The FDA has not approved BPC-157. Its compounding status changed twice in 2026, and neither change is an approval. WADA lists it under section S0.
  • The chain has no aromatic amino acids, no cysteine and no methionine, which shapes how labs detect it by HPLC and how it degrades. Identity needs mass spectrometry.
Important

Research use only. This profile describes the structure of a research peptide and how it is studied in laboratory models. It does not describe human or animal use. Codex Research compounds are not approved by the FDA and are sold for in-vitro laboratory research only.

Quick answer

BPC-157 is a synthetic peptide made of fifteen amino acids, written GEPPPGKPADDAGLV, with a molecular weight of about 1,419.5 Da. Researchers described the sequence in 1993 as a fragment of a larger protein found in human gastric juice and named that protein BPC, for "body protection compound" [1].

In the laboratory, BPC-157 is studied mostly in cell-migration and blood-vessel models. Cell studies link it to several signalling routes, including VEGFR2-Akt-eNOS [3], ERK1/2 [5] and FAK-paxillin [2], and no single receptor has been confirmed. Almost all of the published evidence is preclinical. The FDA has not approved BPC-157 for any use, and WADA prohibits it in sport [15, 17].

BPC-157 at a glance

Property BPC-157
Sequence (one-letter) GEPPPGKPADDAGLV
Sequence (three-letter) Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Length 15 amino acids (a pentadecapeptide)
Molecular formula C62H98N16O22
Molecular weight About 1,419.5 Da (monoisotopic 1,418.7 Da)
Names in the literature BPC 157, PL 14736, "stable gastric pentadecapeptide"
First described 1993, as a fragment of a gastric-juice protein [1]
Confirmed receptor None
Regulatory status Not FDA approved; WADA section S0
Current Codex lot KIZN072426, 99.23% by RP-HPLC

Where BPC-157 comes from

The story starts with a hypothesis about the stomach. In 1993 a group at the University of Zagreb proposed that the stomach responds to stress by releasing protective factors, and reported a protein of about 40,000 Da in human gastric juice that they called BPC [1]. They then characterized a fifteen-residue fragment of it, which they considered essential for its activity, and labelled it BPC 157.

Three points from that origin still matter when you read about the compound:

  1. The research material is synthetic. Every study uses the fifteen-residue peptide made by chemical synthesis. The parent protein is far less documented than the fragment.
  2. The name describes a hypothesis. "Body protection compound" is the label its discoverers chose. It says nothing about the molecule's chemistry.
  3. It has more than one name. Papers from the pharmaceutical company Pliva used the code PL 14736 for the same sequence [6], and many papers write "BPC 157" with a space. A literature search needs all three.

The peptide is also described as "stable" because it is reported to resist breakdown in gastric juice, which is unusual for a peptide [9].

The sequence, residue by residue

A peptide's behaviour in a test follows from its amino acids. BPC-157 has an unusual mix.

Amino acid Count Positions Why it matters
Proline (P) 4 3, 4, 5, 8 Rigid residues that kink the chain and limit how it folds
Glycine (G) 3 1, 6, 13 The smallest residue, adds flexibility between rigid stretches
Aspartic acid (D) 2 10, 11 Acidic; a known site for isomerization during storage [18]
Alanine (A) 2 9, 12 Small and non-reactive
Glutamic acid (E) 1 2 Acidic
Lysine (K) 1 7 The only basic side chain
Leucine (L), valine (V) 1 each 14, 15 Hydrophobic C-terminal end

Three absences are as informative as what is present:

  • No aromatic residues. There is no tryptophan, tyrosine or phenylalanine, so BPC-157 barely absorbs light at 280 nm. Labs detect it through the peptide bond at about 210 to 220 nm.
  • No cysteine or methionine. These are the residues most prone to oxidation. Their absence removes one common degradation route.
  • Three acidic side chains against one basic one. At neutral pH the peptide carries a net negative charge, which affects how it separates on a column.

Suppliers provide BPC-157 as the free peptide or as a salt. The FDA's own compounding documents name two forms, BPC-157 free base and BPC-157 acetate [15]. A counter-ion adds mass that is not peptide, which is one reason the weight of powder in a vial and the amount of peptide are different numbers.

How BPC-157 is studied in the lab

Most mechanistic work falls into five lines. Each comes from cell culture or isolated tissue, and each measures a signalling event in a dish or tissue bath.

Research line Model system Reported finding Source
VEGFR2-Akt-eNOS Human endothelial cells More VEGFR2 expression, receptor internalization and pathway activation [3]
ERK1/2 Human endothelial cells Changed phosphorylation of ERK1/2 and of c-Fos, c-Jun and Egr-1 [5]
Early-response genes Caco-2 cells Faster expression of egr-1 and its repressor nab2 than PDGF-BB [6]
Src-caveolin-1-eNOS Endothelial cells, isolated rat aorta Nitric oxide production; concentration-dependent vessel relaxation [7]
FAK-paxillin, GH receptor Rat tendon fibroblasts More migration and spreading; higher growth hormone receptor expression [2, 4]

Endothelial signalling

The best-characterized work uses endothelial cells, the cells that line blood vessels. One study reported that BPC-157 raised VEGFR2 expression and triggered the VEGFR2-Akt-eNOS cascade, and that blocking receptor internalization suppressed the effect [3]. A second group reported that BPC-157 increased endothelial cell proliferation, migration and tube formation, and changed the phosphorylation of ERK1/2 along with its downstream targets c-Fos, c-Jun and Egr-1 [5].

Nitric oxide and the Src-caveolin-1 route

Nitric oxide appears throughout the BPC-157 literature. Reviews from the Zagreb group describe an interaction with the nitric oxide system across many animal models [8]. A 2020 study gave that idea a mechanism. In isolated rat aorta BPC-157 produced a concentration-dependent relaxation that depended on the endothelium and on nitric oxide. In endothelial cells it increased phosphorylation of Src, caveolin-1 and eNOS, and reduced the binding between caveolin-1 and eNOS that normally holds the enzyme inactive [7].

Early-response genes

Work published under the PL 14736 name looked at egr-1, an immediate-early gene that switches on within minutes of a growth signal. In undifferentiated Caco-2 cells the peptide stimulated expression of egr-1 and its repressor nab2 more quickly than the growth factor PDGF-BB [6]. Egr-1 also appears among the ERK1/2 targets in the endothelial study, so two independent groups reached the same gene from different directions.

Fibroblast migration

In fibroblasts grown from rat Achilles tendon, BPC-157 increased outgrowth, migration and spreading through the FAK-paxillin pathway, and raised expression of the growth hormone receptor [2, 4]. Our BPC-157 vs TB-500 comparison covers these two studies in detail and sets them beside the actin-binding work on TB-500.

What the five lines have in common

All five sit upstream of the same cell behaviours: movement, survival and vessel formation. None identifies the molecule BPC-157 binds first. That gap is the central open question, and it explains why reviews describe the peptide's mechanism as incompletely understood [13, 14].

How BPC-157 breaks down

Two studies describe what happens to the molecule itself.

A 2022 study tracked radiolabelled BPC-157 in rats and dogs. The intact peptide had a plasma half-life of under 30 minutes. It broke down into small peptide fragments and then into single amino acids, which entered normal amino-acid metabolism, and the label left the body mainly through urine and bile [9]. A companion toxicology study in mice, rats, rabbits and dogs reported that the peptide was well tolerated and caused no serious toxicity in those species [10].

The second study came from an anti-doping laboratory that had found BPC-157 in confiscated vials. Its team incubated the peptide in plasma and identified a stable metabolite, then validated a urine method with a detection limit of 0.1 ng/mL. BPC-157 itself stayed stable in urine for at least four days [11].

For a lab, the practical reading is that the intact molecule is short-lived in biological fluids. An experiment that runs for hours in serum-containing medium is measuring the response to a compound that may be partly degraded by the end.

How strong is the evidence?

The honest answer is that the evidence is wide and shallow.

A systematic review published in 2025 searched PubMed, Cochrane and Embase through June 2024. From 544 records it kept 36 studies: 35 preclinical and one clinical. The authors graded the evidence at levels IV and V, the lowest tiers, and found no clinical safety data [12].

Three features of the literature explain that grade:

  1. Concentrated authorship. A large share of BPC-157 papers comes from one research group and its collaborators. Independent groups in Taiwan and China have added mechanistic studies [2, 3, 5, 7], which is why those papers carry weight.
  2. Preclinical scope. Cell culture and rodent models dominate. Reviews written by outside authors note the distance between that base and controlled human data [13, 14].
  3. No confirmed target. A compound with a known receptor can be tested with a blocker or a knockout. BPC-157 research cannot yet do that, so each finding rests on its own experiment.

Read the literature as a set of laboratory hypotheses. Several have been reproduced at the level of cell signalling. None has been established in controlled human trials.

Regulatory status

The FDA has not approved BPC-157 for any human or veterinary use. Codex Research sells it for in-vitro laboratory research only. Our guide to what research use only means explains that designation.

BPC-157's status in pharmacy compounding has moved several times, and the dates matter because older articles describe a position that no longer holds:

Date Event
September 2023 The FDA places BPC-157 in Category 2 of its interim compounding list, citing possible immunogenicity and the difficulty of characterizing peptide impurities [15]
April 2026 The FDA removes BPC-157 from Category 2 after the nominations are withdrawn [15]
July 2026 The FDA's Pharmacy Compounding Advisory Committee votes 8 to 6, with one abstention, to recommend adding BPC-157 free base and acetate to the compounding list [16]

An advisory vote is a recommendation to the agency. It does not amend the list, and nothing in this sequence is an approval of BPC-157 as a drug. This section reflects the position in November 2026.

In sport, the World Anti-Doping Agency names BPC-157 as an example under section S0 of the Prohibited List, which covers substances with no current approval for human therapeutic use [17].

Reading a BPC-157 certificate

A certificate of analysis describes one lot. Here is the report for the current Codex lot, KIZN072426, tested by Optiq Health Labs under report 0327.OPT.260729-R1 and reported on August 3, 2026. The same table appears on the BPC-157 product page.

Test Specification Method Result
Identity BPC-157 LC-MS BPC-157
Potency (assay) Report HPLC 4.85 mg
Purity ≥ 98.0% RP-HPLC 99.23%
pH 5.0 to 8.0 Probe 5.90
Water activity Report Probe 0.2457 aw
Endotoxin ≤ 0.05 EU/mg LAL Pass
Sterility No growth USP <71> No growth
Yeast and mold Within limits USP <61>/<62> Pass
Residual solvents 22 analytes GC-MS None detected
Heavy metals (As, Cd, Pb, Hg) Within limits ICP-OES None detected

What each group of lines tells you:

  1. Identity. LC-MS confirms the main component has the mass of BPC-157. For this sequence, expect a singly charged ion near m/z 1,419.7 and a doubly charged ion near m/z 710.4.
  2. Purity. 99.23% of the detected material is the target peptide, above the 98.0% specification. Our guide to purity grades explains what the remaining fraction can contain.
  3. Potency. The assay measured 4.85 mg against a 5 mg label, or 97% of label. Residual water and counter-ion account for gaps of this size in a lyophilized powder.
  4. Water activity. A value of 0.2457 aw indicates a dry cake, which supports stability in storage.
  5. Contaminants. Endotoxin, sterility, solvents and metals each pass against a stated limit. What endotoxin testing means covers the first of these.

To check that a report is genuine, confirm it with the laboratory that issued it. Our guide to third-party testing gives the steps, and HPLC vs mass spec explains why identity and purity need different instruments.

Stability and storage as a research material

BPC-157 is supplied as a lyophilized powder. Like most freeze-dried peptides it is hygroscopic, so moisture is the first risk to a sealed vial, followed by heat and light.

Its chemistry points to one specific weakness. The two neighbouring aspartic acid residues at positions 10 and 11 are sites where a peptide backbone can isomerize or cleave over time, a route described for peptides and proteins generally [18]. The missing cysteine and methionine work in its favour, because oxidation at those residues is a common problem that this sequence avoids.

Sealed vials are kept cold, dry and away from light, with the lot number kept beside the vial. Research peptides in transit explains what heat and time do to a freeze-dried vial between dispatch and delivery.

Planning in-vitro work with BPC-157

The points below are general research practice applied to this compound.

  1. Pick readouts that match a pathway. Western blots for phosphorylated Akt, eNOS, ERK1/2, Src or FAK test the reported signalling directly. A migration or tube-formation assay shows an outcome and cannot say which route produced it.
  2. Work in molar units. One milligram of BPC-157 is about 0.70 micromoles. Comparing it by weight with a smaller peptide such as TB-500 compares different numbers of molecules.
  3. Account for degradation. Because the intact peptide is short-lived in plasma [9], note the medium, the serum content and the duration of each experiment.
  4. Include a positive control. VEGF in an endothelial assay, or PDGF-BB in a fibroblast assay, shows that the system can respond.
  5. Keep one lot per study and record it. Purity, peptide content and counter-ion vary between lots. The lot number, purity and identity result belong in the study record.

Common misconceptions

"BPC-157 has a known receptor." It does not. Several pathways respond to it in cell models, and the first binding partner is unidentified.

"It is a natural gut hormone." The sequence was reported as part of a gastric-juice protein. The research compound is synthetic, and no circulating form of the fragment is well characterized.

"The FDA banned it" or "the FDA approved it." Neither is accurate. BPC-157 has never been approved, and its compounding status has changed more than once.

"A high purity number proves it is BPC-157." HPLC purity measures how much of the sample is the main component. Mass spectrometry confirms what that component is.

"BPC-157 and TB-500 are versions of the same thing." They share no sequence and are studied through different mechanisms.

BPC-157 is most often discussed beside TB-500, a seven-residue fragment of thymosin beta-4. The two are unrelated, and our BPC-157 vs TB-500 comparison sets out the differences in structure, mechanism and evidence.

Codex Research supplies BPC-157 on its own and in three research blends: Wolverine pairs it with TB-500, Glow adds GHK-Cu, and Klow adds GHK-Cu and KPV. Glow vs Klow compares the last two, and What is GHK-Cu? profiles the copper peptide they share. For attribution, studies that use a blend usually run the single peptides alongside it.

What this profile does not tell you

This profile covers structure, origin, the research literature, regulation and testing. It does not describe how BPC-157 behaves in any person or animal, establish safety or effectiveness for any purpose, or replace the certificate for the lot you hold. Research compounds are not approved by the FDA for human or veterinary use.

How Codex Research documents BPC-157

Every Codex BPC-157 lot ships with a lot-matched certificate of analysis from an independent laboratory, published on the product page. The current report confirms identity by LC-MS, purity by RP-HPLC and potency by HPLC, and adds endotoxin, sterility, residual-solvent and heavy-metal results. Match the lot number on the page to your vial before use. For the full report on any lot, contact info@codexresearch.shop.

Frequently asked questions

What is BPC-157?
BPC-157 is a synthetic peptide made of fifteen amino acids in the order Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It was described in 1993 as a fragment of a larger protein found in gastric juice, and it is used as a research compound in cell and animal models.
What does BPC stand for?
Body protection compound. The name was given to a protein of about 40,000 Da reported in human gastric juice. The number 157 identifies the 15-amino-acid fragment that researchers went on to synthesize and study.
What is the amino acid sequence of BPC-157?
GEPPPGKPADDAGLV in one-letter code: glycine, glutamic acid, three prolines, glycine, lysine, proline, alanine, two aspartic acids, alanine, glycine, leucine and valine.
What is the molecular weight of BPC-157?
About 1,419.5 Da for the free peptide, with the molecular formula C62H98N16O22. On a mass spectrometer it usually appears as a singly charged ion near m/z 1,419.7 and a doubly charged ion near m/z 710.4.
Is BPC-157 a natural peptide?
The sequence was reported as part of a protein in gastric juice, but the material used in research is made by chemical synthesis. There is no well-characterized circulating form of the 15-residue peptide.
How does BPC-157 work?
No single receptor has been confirmed. Cell studies associate it with several signalling routes: VEGFR2-Akt-eNOS in endothelial cells, ERK1/2 and its downstream targets, the Src-caveolin-1-eNOS pathway that produces nitric oxide, and FAK-paxillin in tendon fibroblasts.
What is BPC-157 studied for in the lab?
Mainly cell migration, blood-vessel formation and growth-factor signalling. Typical systems are endothelial cells, tendon fibroblasts, isolated vessel preparations and rodent models.
Is there human research on BPC-157?
Almost none. A 2025 systematic review identified 36 eligible studies published from 1993 to 2024, of which 35 were preclinical and one was clinical. The reviewers found no clinical safety data.
Is BPC-157 FDA approved?
No. The FDA has not approved BPC-157 for any use. Codex Research sells it for in-vitro laboratory research only.
What changed with the FDA and BPC-157 in 2026?
In April 2026 the FDA removed BPC-157 from Category 2 of its interim compounding list after the nominations were withdrawn. In July 2026 an FDA advisory committee voted 8 to 6 to recommend adding it to the compounding list. A recommendation does not change the list and is not an approval.
Is BPC-157 banned in sport?
Yes. The World Anti-Doping Agency names BPC-157 as an example under section S0 of the Prohibited List, which covers substances with no current approval for human therapeutic use.
How do you confirm that a vial contains BPC-157?
By mass spectrometry, usually LC-MS. The measured mass should match the theoretical mass of the sequence, about 1,419.5 Da. HPLC purity alone shows how much of the material is the main component, not what that component is.
Why is BPC-157 measured at 214 nm and not 280 nm?
The sequence has no tryptophan, tyrosine or phenylalanine, the amino acids that absorb light near 280 nm. Labs detect it through the peptide bond, which absorbs in the low ultraviolet range around 210 to 220 nm.
How is BPC-157 different from TB-500?
They are unrelated molecules. BPC-157 has fifteen residues and is studied mainly through growth-factor and angiogenic signalling. TB-500 is a seven-residue fragment of thymosin beta-4 studied for actin binding.
How should BPC-157 be stored as a research material?
It is supplied as a lyophilized powder. Sealed vials are kept cold, dry and away from light, and the lot number stays with the vial so it can be matched to its certificate.

References

  1. Sikirić P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993;87(5):313-327.
  2. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780.
  3. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95(3):323-333.
  4. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077.
  5. Huang T, Zhang K, Sun L, et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther. 2015;9:2485-2499.
  6. Tkalcević VI, Cuzić S, Brajsa K, et al. Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. Eur J Pharmacol. 2007;570(1-3):212-221.
  7. Hsieh MJ, Lee CH, Chueh HY, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10(1):17078.
  8. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des. 2014;20(7):1126-1135.
  9. He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182.
  10. Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665.
  11. Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal. 2017;9(10):1490-1498.
  12. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485-495.
  13. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review. Pharmaceuticals (Basel). 2025;18(2):185.
  14. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159.
  15. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks.
  16. McDermott. Bulk-list bound? PCAC backs majority of peptides in two-day public meeting. Client alert, July 27, 2026.
  17. World Anti-Doping Agency. The Prohibited List, section S0: Non-approved substances.
  18. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575.
For research use only. This article summarizes published laboratory and preclinical literature for reference. It is not medical advice. Codex Research products are not FDA approved and are not for human or animal consumption or for any clinical or medical use.

Shop the lab

Popular research peptides

BPC-157Repair

Research peptide

BPC-157

Tissue-Repair Research

BPC-157 is a 15-amino-acid synthetic peptide taken from a gastric-juice protein, studied in endothelial, fibroblast and growth-factor research. Lot-tested by HPLC and LC-MS.

99%+Purity+149Reward pts
$59.99
View product
TB-500Repair

Research peptide

TB-500

Tissue-Repair Research

TB-500 is Ac-LKKTETQ, the acetylated actin-binding fragment of Thymosin Beta-4 (residues 17–23), supplied as a lyophilized peptide for actin-regulation and cell-migration research.

99%+Purity+187Reward pts
$74.99
View product
GHK-CuDermal

Research peptide

GHK-Cu

Dermal Matrix Research

GHK-Cu is the copper(II) complex of the tripeptide Gly-His-Lys, a constituent of human plasma, studied in fibroblast matrix and copper-transport research. Lot-tested by HPLC.

99%+Purity+99Reward pts
$39.99
View product
GlowBlends

Research peptide

Glow

Repair Blend

Glow is a three-peptide research blend: 49.87 mg GHK-Cu, 9.88 mg BPC-157 and 9.32 mg TB-500 per vial on the current lot, measured by HPLC and tested on a full safety panel.

99%+Purity+237Reward pts
$94.99
View product
NAD+Cellular

Research peptide

NAD+

Cellular Research

NAD+ is nicotinamide adenine dinucleotide, the oxidized redox coenzyme and sirtuin substrate, supplied as lyophilized powder in 500 mg and 1000 mg vials. Lot-tested by LC-MS.

99%+Purity+224Reward pts
$89.99
View product
KlowBlends

Research peptide

Klow

Repair Blend

Klow is a four-peptide research blend: 51.33 mg GHK-Cu, 11.55 mg KPV, 9.32 mg TB-500 and 8.00 mg BPC-157 per vial on the current lot, for multi-pathway laboratory research.

99%+Purity+249Reward pts
$99.99
View product
Melanotan IIDermal

Research peptide

Melanotan II

Melanocortin Research

Melanotan II is a cyclic lactam analog of alpha-MSH that binds the melanocortin receptors, lot-tested at 99.91% purity with a published certificate.

99%+Purity+112Reward pts
$44.99
View product
IpamorelinGH axis

Research peptide

Ipamorelin

GH-Axis Research

Ipamorelin is a five-residue synthetic peptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, studied as a selective agonist at the ghrelin receptor. Lot-tested by RP-HPLC.

99%+Purity+87Reward pts
$34.99
View product
SemaxNeuro

Research peptide

Semax

Neuropeptide Research

Semax is a seven-residue ACTH(4-7) analogue with a Pro-Gly-Pro tail, studied in BDNF, trkB and cholinergic-neuron research. 5 mg and 10 mg vials, lot-tested by LC-MS.

99%+Purity+124Reward pts
$49.99
View product
SelankNeuro

Research peptide

Selank

Neuropeptide Research

Selank is a seven-residue tuftsin analogue, Thr-Lys-Pro-Arg-Pro-Gly-Pro, studied in enkephalinase and neurotransmission gene-expression research. Lot-tested by LC-MS.

99%+Purity+112Reward pts
$44.99
View product

Keep reading

Compound Profiles
November 10, 2026

What Is GHK-Cu? The Copper Peptide in Lab Research

GHK-Cu is three amino acids wrapped around a copper ion, and that copper is the reason the powder is blue. This profile covers what the molecule is, how tightly it holds its metal, what fifty years of cell-culture research report, where the evidence is thin, and what a certificate for a copper peptide should show.

Read Article
Compound Profiles
November 9, 2026

Glow vs Klow: How the Two Research Peptide Blends Differ

Glow and Klow share three of their peptides. The difference is one small molecule, KPV, and everything that follows from adding it: a fourth research pathway, a higher total mass and a harder job for the testing lab. This guide compares the two blends component by component.

Read Article
Purity & COAs
November 14, 2026

What a Peptide Certificate of Analysis Can't Tell You

A certificate of analysis reports the tests a lab ran on one sample on one date. This guide sets out eight things the page cannot tell you, from untested properties and method blind spots to storage after the test, and names the document that fills each gap.

Read Article

From lab to your door

Every compound.Every lot, proven.

U.S.-made research vials, shipped with lot-matched, lab-tested COAs you can scan straight off the label.